Publication: From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand
Issued Date
2019-05-01
Resource Type
ISSN
22121102
22121099
22121099
Other identifier(s)
2-s2.0-85056346201
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Value in Health Regional Issues. Vol.18, (2019), 47-53
Suggested Citation
Ronnachai Kongsakon, Surasit Lochid-amnuay, Nattiya Kapol, Oraluck Pattanaprateep From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand. Value in Health Regional Issues. Vol.18, (2019), 47-53. doi:10.1016/j.vhri.2018.08.004 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50776
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
From Research to Policy Implementation: Trastuzumab in Early-Stage Breast Cancer Treatment in Thailand
Other Contributor(s)
Abstract
© 2018 Objectives: To evaluate the adjuvant therapy of trastuzumab cost and quality-adjusted life-years (QALYs) in lifetime horizon and describe the use of an economic evaluation in supporting policy-making decisions in the treatment of early-stage breast cancer in Thailand. Methods: A Markov model was used to evaluate the cost effectiveness of 1-year adjuvant trastuzumab for patients with early-stage breast cancer who were considered human epidermal growth factor receptor 2/neu-positive with a societal perspective and lifetime horizon. The research variables were probability of health state change, health utility, and cost of treatment. A sensitivity analysis was conducted using probabilistic methods. A budget impact analysis was also performed. Results: The results revealed that the treatment cost and QALYs in the trastuzumab group yielded 4.59 QALYs. The incremental cost-effectiveness ratio was $3387 (THB 118 572; THB = Thai baht) per QALY. On the basis of the willingness-to-pay threshold in Thailand, a 1-year adjuvant trastuzumab treatment for breast cancer was a cost-effective therapy. Conclusions: A combination therapy that includes trastuzumab is a preferable choice and should be used in early-stage breast cancer treatment. The Thai government has listed trastuzumab on the National List of Essential Medicines to be used for the early stages of breast cancer since 2014.